Literature DB >> 3247321

The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats.

P S Leppert1, M Cortese, J A Fix.   

Abstract

The effects of carbidopa dose and time and route of administration on systemic plasma levels of parenterally and nonparenterally administered L-dopa were examined in rats. Intravenous coadministration of L-dopa + carbidopa resulted in significant (P less than 0.05) carbidopa-dependent increases in both the area under the plasma L-dopa concentration versus time profile (AUC; +27%) and the plasma L-dopa half-life (t1/2; +35%). Simultaneous duodenal or rectal carbidopa administration did not alter the L-dopa i.v. pharmacokinetic profile. Carbidopa pretreatment significantly increased the i.v. L-dopa AUC (+38 and +82% for i.v. and duodenal pretreatments, respectively) compared to simultaneous administration. Both i.v. and duodenal carbidopa increased duodenal L-dopa AUC to a similar extent (+282 and +239% for i.v. and duodenal administration, respectively). Rectal studies indicated poor absorption of both L-dopa and carbidopa, with no demonstrable effect on plasma L-dopa. The results indicate that the timing and route of carbidopa and L-dopa administration are important in determining the extent of i.v. or duodenal L-dopa systemic availability. The rat model affords results similar to those reported in human studies and may be useful for more extensive evaluation of L-dopa and carbidopa interactions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3247321     DOI: 10.1023/a:1015946114321

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA.

Authors:  C C PORTER; L S WATSON; D C TITUS; J A TOTARO; S S BYER
Journal:  Biochem Pharmacol       Date:  1962-11       Impact factor: 5.858

2.  A method for the determination of some amino acid decarboxylases.

Authors:  V E DAVIS; J AWAPARA
Journal:  J Biol Chem       Date:  1960-01       Impact factor: 5.157

3.  Aromatic L-amino acid decarboxylase.

Authors:  W LOVENBERG; H WEISSBACH; S UDENFRIEND
Journal:  J Biol Chem       Date:  1962-01       Impact factor: 5.157

4.  Effect of supplemental carbidopa on bioavailability of L-dopa.

Authors:  J M Cedarbaum; H Kutt; A K Dhar; S Watkins; F H McDowell
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

5.  L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.

Authors:  L Rivera-Calimlim; J P Morgan; C A Dujovne; J R Bianchine; L Lasagna
Journal:  Biochem Pharmacol       Date:  1971-11       Impact factor: 5.858

6.  Interaction of L-alpha-methyl-alpha-hydrazino-3,4 dihydroxyphenylpropionic acid with dopa-decarboxylase from pig kidney.

Authors:  C Borri-Voltattorni; A Minelli; P Borri
Journal:  FEBS Lett       Date:  1977-03-15       Impact factor: 4.124

7.  The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa.

Authors:  S Kaakkola; P T Männistö; E Nissinen; A Vuorela; R Mäntylä
Journal:  Acta Neurol Scand       Date:  1985-10       Impact factor: 3.209

8.  Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.

Authors:  R P Lesser; S Fahn; S R Snider; L J Cote; W P Isgreen; R E Barrett
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

9.  Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.

Authors:  F Bermejo Pareja; P Martinez-Martin; V Muradas; J G de Yébenes
Journal:  Acta Neurol Scand       Date:  1985-11       Impact factor: 3.209

10.  Blood-brain barrier to carbidopa (MK-486) and Ro 4-4602, peripheral dopa decarboxylase inhibitors.

Authors:  W G Clark; W H Oldendorf; W G Dewherst
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

View more
  8 in total

1.  Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.

Authors:  Lissa S Brod; Jason L Aldred; John G Nutt
Journal:  Mov Disord       Date:  2012-04-16       Impact factor: 10.338

2.  A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.

Authors:  S Grange; N H Holford; T W Guentert
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

3.  A comparison of oral and rectal absorption of L-dopa esters in rats and mice.

Authors:  J A Fix; J Alexander; M Cortese; K Engle; P Leppert; A J Repta
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

4.  Sinemet-ferrous sulphate interaction in patients with Parkinson's disease.

Authors:  N R Campbell; D Rankine; A E Goodridge; B B Hasinoff; M Kara
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

5.  Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.

Authors:  E Bredberg; H Lennernäs; L Paalzow
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

6.  Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption.

Authors:  J A Fix; J Alexander; M Cortese; K Engle; P Leppert; A J Repta
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

7.  Effect of Rectal Levodopa Administration: A Case Report.

Authors:  Jolanda M J Vogelzang; Marianne Luinstra; A Wijnand F Rutgers
Journal:  Case Rep Neurol       Date:  2015-10-21

Review 8.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.